Models of Depression Used in the Pharmaceutical Industry

  • James L. Howard
  • Robert M. Ferris
  • Barrett R. Cooper
  • Francis E. Soroko
  • Ching M. Wang
  • Gerald T. Pollard


An animal model is a representation of some aspects of a human disease. Modeling mental disease is problematic in that the symptoms may be poorly defined and the underlying pathophysiology poorly understood. This is especially true of depression, which is the name given to a heterogeneous group of disorders having in common the disturbance of mood (Cronholm, 1984; Klerman, 1984; Baldessarini, 1985). Models of depression are made primarily for two reasons: to allow experimental manipulation of behavioral and biochemical variables that might provide insight into the etiology and underlying pathophysiology of the disease and to allow prediction of how a variable such as an antidepressant drug might affect the disease (Everitt and Keverne, 1979).


Locus Coeruleus Antidepressant Drug Antidepressant Activity Postsynaptic Receptor Presynaptic Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson LY, Seligman MEP (1977): Modelling psychopathology in the laboratory: History and rationale. In: Psychopathology: Experimental Models, Maser JD, Seligman MEP, eds. San Francisco: FreemanGoogle Scholar
  2. Aghajanian GK, Lakoski JM (1984): Hyperpolarization of serotonergic neurons by serotonin and LSD: Studies in brain slices showing increased K+ conductance. Brain Res 305:181–185PubMedCrossRefGoogle Scholar
  3. Aprison MH, Hingtgen JN (1981): Hypersensitive serotonergic receptors: A new hypothesis for one subgroup of unipolar depression derived from an animal model. In: Serotonin—Current Aspects of Neurochemistry and Function, Haber B, Gabay S, Alivisatos S, Issidorides M, eds. New York: PlenumGoogle Scholar
  4. Aprison MH, Takahashi R, Tachiki K (1978): Hypersensitive serotonergic receptors involved in clinical depression—A theory. In: Neuropharmacology and Behavior, Haber B, Aprison MH, eds. New York: PlenumGoogle Scholar
  5. Atrens DM (1984): Self-stimulation and psychotropic drugs: A methodological and conceptual critique. In: Animal Models in Psychopathology, Bond NW, ed. New York: Academic PressGoogle Scholar
  6. Baldessarini RJ (1985): Drugs and the treatment of psychiatric disorders. In: Goodman and Gilmans The Pharmacological Basis of Therapeutics, Gilman AG, Goodman LS, Rall TW, Murad F, eds. New York: MacmillanGoogle Scholar
  7. Bond NW (1984): Animal models in psychopathology: An introduction. In: Animal Models in Psychopathology, Bond NW, ed. New York: Academic PressGoogle Scholar
  8. Browne RG (1979): Effects of antidepressants and anticholinergics in a mouse “behavioral despair” test. Eur J Pharmacol 58:331–334PubMedCrossRefGoogle Scholar
  9. Brunello N, Barbaccia ML, Chuang DM, Costa E (1982): Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine: Permissive role of serotonergic axons. Neuropharmacology 21:1145–1149PubMedCrossRefGoogle Scholar
  10. Bunney WE Jr, Davis JM (1965): Norepinephrine in depressive reactions: A review. Arch Gen Psychiatry 13:483–494PubMedCrossRefGoogle Scholar
  11. Cairncross KD (1984): Olfactory bulbectomy as a model of depression. In: Animal Models in Psychopathology, Bond NW, ed. New York: Academic PressGoogle Scholar
  12. Carlsson A (1984): Current theories on the mode of action of antidepressant drugs. Adv Biochem Psychopharmacol 39:213–221PubMedGoogle Scholar
  13. Charney DS, Menkes DB, Heninger GR (1981): Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 38:1160–1180PubMedCrossRefGoogle Scholar
  14. Cooper BR, Howard JL, Soroko FE (1983): Animal models used in prediction of antidepressant effects in man. J Clin Psychiatry 44:63–66PubMedGoogle Scholar
  15. Cornfeldt M, Fisher B, Fielding S (1982): Rat internal capsule lesion: A new test for detecting antidepressants. Fed Proc 41:1066Google Scholar
  16. Cowen PJ, Grahame-Smith DG (1983): Abstract. In: Preclinical Psychopharma-cology, Grahame-Smith DG, Cowen PJ, eds. Amsterdam: Excerpta MedicaGoogle Scholar
  17. Cowen PJ, Grahame-Smith DG, Green AR, Heal DJ (1982): β-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses. Br J Pharmacol 76:265–270PubMedGoogle Scholar
  18. Crawley JN (1984): Preliminary report of a new rodent separation model of depression. Prog Neuropsychopharmacol Biol Psychiatry 8:447–457PubMedGoogle Scholar
  19. Cronholm, B (1984): The concept of depression: Diagnosis and Classification. In: Frontiers in Biochemical and Pharmacological Research in Depression, Usdin E, Asberg M, Bertilsson L, Sjöqvist F, eds. New York: Raven PressGoogle Scholar
  20. De Graaf JS, Van Riezen H, Berendsén HHG, Van Delft AML (1985): A set of behavioural tests predicting antidepressant activity. Drug Dev Res 5:291–301CrossRefGoogle Scholar
  21. Delini-Stula A (1980): Drug-induced alterations in animal behavior as a tool for the evaluation of antidepressants: Correlation with biochemical effects. In: Psychotropic Agents, Part I: Antipsychotics and Antidepressants, Hoffmeister F, Stille G, eds. Berlin: Springer-VerlagGoogle Scholar
  22. Dingledine R, ed. (1984): Brain Slices. New York: PlenumGoogle Scholar
  23. Dingledine R, Dodd J, Kelly JS (1980): The in vitro brain slice as a useful neurophys-iological preparation for intracellular recording. J Neurosci Methods 2:323–362PubMedCrossRefGoogle Scholar
  24. Engberg G, Svensson TH (1980): Mianserin: Direct alteration of brain norepinephrine neurons by blocking alpha2-receptors. Commun Psychopharmacol 4:233–239PubMedGoogle Scholar
  25. Everett GM (1967): The dopa response potentiation test and its use in screening for antidepressant drugs. In: Antidepressant Drugs, Garattini S, Dukes M, eds. Amsterdam: Excerpta MedicaGoogle Scholar
  26. Everitt BJ, Keverne EB (1979): Models of depression based on behavioral observations of experimental animals. In: Psychopharmacology of Affective Disorders, Paykel ES, Coppen A, eds. New York: Oxford University PressGoogle Scholar
  27. Ferris RM, Beaman OJ (1983): Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β- adrenergic, serotonergic (5-HT2), α 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 22:1257–1267PubMedCrossRefGoogle Scholar
  28. Ferris RM, White HL, Cooper BR, Maxwell RA, Tang FLM, Beaman OJ, Russell A (1981): Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin®). Drug Dev Res 1:21–35CrossRefGoogle Scholar
  29. Frazer A, Lucki I, Sills M (1985): Alterations in monoamine-containing neuronal function due to administration of antidepressants repeatedly to rats. Acta Pharmacol Toxicol 56 (Suppl l):21–34Google Scholar
  30. Frazer A, Pandey G, Mendels J, Neeley S, Kane M, Hess ME (1974): The effects of tri-iodothyronine in combination with imipramine on [3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology 13:1131–1140CrossRefGoogle Scholar
  31. Fuller RW (1986): Pharmacologic modification of serotonergic function: Drugs for the study and treatment of psychiatric and other disorders. J Clin Psychiatry 47 (Suppl 4):4–8PubMedGoogle Scholar
  32. Fuller RW, Wong DT (1985): Effects of antidepressants on uptake and receptor systems in the brain. Prog Neuropsychopharmacol Biol Psychiatry 9:485–490PubMedCrossRefGoogle Scholar
  33. Gershon S, Holmberg G, Mattsson E, Mattsson N, Marshall A (1962): Imipramine hydrochloride: Its effects on clinical, autonomic and physiological functions. Arch Gen Psychiatry 6:96–101PubMedCrossRefGoogle Scholar
  34. Gluckman MI, Baum T (1969): The pharmacology of iprindole, a new antidepressant. Psychopharmacologia 15:169–185PubMedGoogle Scholar
  35. Goldstein JM, Malick JB (1983): An automated descending rate-intensity self-stimulation paradigm: Usefulness for distinguishing antidepressants from neuroleptics. Drug Dev Res 3:29–35CrossRefGoogle Scholar
  36. Green AR (1985): Antidepressant treatments and serotonin receptor number and function. Acta Pharmacol Toxicol 56 (Suppl 1):128–137Google Scholar
  37. Horovitz ZP (1966): The relationship of the amygdala to the mechanism of action of two types of antidepressants. In: Recent Advances in Biological Psychiatry, Wortis J, ed. New York: PlenumGoogle Scholar
  38. Howard JL, Pollard GT (1983): Are primate models of neuropsychiatric disordersGoogle Scholar
  39. useful to the pharmaceutical industry? In: Ethopharmacology: Primate Models of Neuropsychiatric Disorders. Miczek KA, ed. New York: Alan R. LissGoogle Scholar
  40. Howard JL, Soroko FE, Cooper BR (1981): Empirical behavioral models of depression, with emphasis on tetrabenazine antagonism. In: Antidepressants: Neurochemical, Behavioral and Clinical Perspectives, Enna SJ, Malick JB, Richelson E, eds. New York: Raven PressGoogle Scholar
  41. Janowsky A, Okada F, Manier DH, Applegate CD, Sulser F, Steranka L (1982): Role of serotonergic input in the regulation of the β-adrenergic receptor-coupled adenylate cyclase system. Science 218:900–901PubMedCrossRefGoogle Scholar
  42. Jesberger JA, Richardson JS (1985): Animal models of depression: Parallels and correlates to severe depression in humans. Biol Psychiatry 20:764–784PubMedCrossRefGoogle Scholar
  43. Johnston JP (1968): Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297PubMedCrossRefGoogle Scholar
  44. Jones CN, Howard JL, McBennett ST (1980): Stimulus properties of antidepressants in the rat. Psychopharmacology 67:111–118PubMedCrossRefGoogle Scholar
  45. Katz RJ (1981): Animal models and human depressive disorders. Neurosci Biobehav Rev 5:231–246PubMedCrossRefGoogle Scholar
  46. Kerkut GA, Wheal HV, eds. (1981): Electrophysiology of Isolated Mammalian CNS Preparations. New York: Academic PressGoogle Scholar
  47. Klerman GL (1984): History and development of modern concepts of affective illness. In: Neurobiology of Mood Disorders, Post RM, Ballenger JC, eds. Baltimore: Williams and WilkinsGoogle Scholar
  48. Kuhn R (1958): The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 115:459–464PubMedGoogle Scholar
  49. Lecrubier Y, Puech AJ, Jouvent R, Simon P, Widloch D (1980): A beta adrenergic stimulant (salbutamol) versus clomipramine in depression: A controlled study. Br J Psychiatry 136:354–358PubMedCrossRefGoogle Scholar
  50. Leith NJ, Barrett RJ (1980): Effects of chronic amphetamine or reserpine on self-stimulation responding: Animal model of depression? Psychopharmacology 72: 9–15PubMedCrossRefGoogle Scholar
  51. Leonard BE (1984): Pharmacology of new antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 8:97–108PubMedCrossRefGoogle Scholar
  52. Liebman JM (1983): Discriminating between reward and performance: A critical review of intracranial self-stimulation methodology. Neurosci Biobehav Rev 7: 45–72PubMedCrossRefGoogle Scholar
  53. Lloyd KG, Pilc A (1984): Chronic antidepressants and GABA synapses. Neuropharmacology 23:841–842CrossRefGoogle Scholar
  54. Maas JW (1975): Biogenic amines and depression: Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry 32:1357–1361PubMedCrossRefGoogle Scholar
  55. Maier SF (1984): Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 8:435–446PubMedGoogle Scholar
  56. Maj J, Przegalinski E, Mogilnicka E (1984): Hypotheses concerning the mechanism of action of antidepressant drugs. Rev Physiol Biochem Pharmacol 100:1–74PubMedGoogle Scholar
  57. Malick JB (1983): Potentiation of yohimbine-induced lethality in mice: Predictor of antidepressant potential. Drug Dev Res 3:357–363CrossRefGoogle Scholar
  58. Mandell AJ, Segal DS, Kuczenski R (1975): Metabolic adaptation to antidepressant drugs: Implications for pathophysiology and treatment in psychiatry. In: Catecholamines and Behavior. 2. Neuro Psychopharmacology, Friedhoff AJ, ed. New York: PlenumGoogle Scholar
  59. Maxwell RA (1983): Second generation antidepressants: The pharmacological and clinical significance of selected examples. Drug Dev Res 3:203–211CrossRefGoogle Scholar
  60. Maxwell RA (1984): The state of the art of the science of drug discovery—an opinion. Drug Dev Res 4:375–389CrossRefGoogle Scholar
  61. McKinney WT Jr, Bunney WE Jr (1969): Animal model of depression. I. Review of evidence: implications for research. Arch Gen Psychiatry 21:240–248PubMedCrossRefGoogle Scholar
  62. McKinney WT Jr (1974): Animal models in psychiatry. Perspect Biol Med 17:529–541PubMedGoogle Scholar
  63. McKinney WT Jr (1977): Biobehavioral models of depression in monkeys. In: Animal Models in Psychiatry and Neurology, Hanin I, Usdin E, eds. Oxford: Pergamon PressGoogle Scholar
  64. Mishra R, Janowsky A, Sulser F (1980): Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: Subsensitivity without reduction in β-adrenergic receptor binding. Neuropharmacology 19:983–988PubMedCrossRefGoogle Scholar
  65. Nagayama N, Hingtgen JN, Aprison MH (1981): Postsynaptic action by four antidepressive drugs in an animal model of depression. Pharmacol Biochem Behav 15:125–130PubMedCrossRefGoogle Scholar
  66. Nybäck HV, Walters JR, Aghajanian GK, Roth RH (1975): Tricyclic antidepressants: Effects on the firing rate of brain noradrenergic neurons. Eur J Pharmacol 32:302–312PubMedCrossRefGoogle Scholar
  67. Olds J, Milner P (1954): Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47:419–427PubMedCrossRefGoogle Scholar
  68. Pollard GT, Howard JL (1986): Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule. Psychopharmacology 89:253–258PubMedCrossRefGoogle Scholar
  69. Porsolt RD, Le Pichon M, Jalfre M (1977): Depression: A new animal model sensitive to antidepressant treatments. Nature 266:730–732PubMedCrossRefGoogle Scholar
  70. Porsolt RD (1983): Failure of repeated peer separations to induce depression in infant rhesus monkeys. Drug Dev Res 3:567–572CrossRefGoogle Scholar
  71. Quinton RM (1963): The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol 21:51–66Google Scholar
  72. Racagni G, Mocchetti I, Calderini G, Battistella A, Brunello N (1983): Temporal sequence of changes in central noradrenergic system of rat after prolonged antidepressant treatment: Receptor desensitization and neurotransmitter interactions. Neuropharmacology 22:415–424PubMedCrossRefGoogle Scholar
  73. Rastogi SK, McMillan DE (1985): Effects of some typical and atypical antidepressants on schedule-controlled responding in rats. Drug Dev Res 5:243–250CrossRefGoogle Scholar
  74. Richelson E, El-Fakahany E (1982): Changes in the sensitivity of receptors for neurotransmitters and the actions of some psychotherapeutic drugs. Mayo Clin Proc 57:576–582PubMedGoogle Scholar
  75. Richelson E, Pfenning M (1984): Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286PubMedCrossRefGoogle Scholar
  76. Rubin B, Malone MH, Waugh MH, Burke JC (1957): Bioassay of Rauwolfia roots and alkaloids. J Pharmacol Exp Ther 120:125–136PubMedGoogle Scholar
  77. Russell RW, Overstreet DH (1984). Animal models in neurobehavioral toxicology. In: Animal Models in Psychopathology, Bond NW, ed. New York: Academic PressGoogle Scholar
  78. Sanghvi I, Bindler E, Gershon S (1969): The evaluation of a new animal method for the prediction of clinical anti-depressant activity. Life Sci 8:99–106PubMedCrossRefGoogle Scholar
  79. Sansone M, Melzacka M, Hano J, Vetulani J (1983): Reversal of depressant action of trazodone on avoidance behaviour by its metabolite m-chlorophenylpiperazine. J Pharm Pharmacol 35:189–190PubMedCrossRefGoogle Scholar
  80. Scuvée-Moreau JJ, Dresse AE (1979): Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur J Pharmacol 57:219–225PubMedCrossRefGoogle Scholar
  81. Seiden LS, O’Donnell JM (1985): Effects of antidepressant drugs on DRL behavior. In: Behavioral Pharmacology: The Current Status, Seiden LS, Balster RL, eds. New York: Alan R. LissGoogle Scholar
  82. Sellinger-Barnette MM, Mendels J, Frazer A (1980): The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology 19:447–454PubMedCrossRefGoogle Scholar
  83. Sheard MH, Zolovick A, Aghajanian GK (1972). Raphe neurons: Effect of tricyclic antidepressant drugs. Brain Res 43:690–694PubMedCrossRefGoogle Scholar
  84. Sulser F (1978): Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: Molecular approaches to an understanding of affective disorders. Pharmakopsychiatry Neuropsychopharmakol 11:43–52Google Scholar
  85. Sulser F (1982): Regulation and adaptation of central norepinephrine receptor systems: Modification by antidepressant treatments. Psychiatr J Univ Ottawa 7:196–203Google Scholar
  86. Sulser F, Vetulani J, Mobley PL (1978): Commentary: Mode of action of antidepressant drugs. Biochem Pharmacol 27:257–261PubMedCrossRefGoogle Scholar
  87. Trulson ME (1984): Pharmacological investigation of CNS unit responses in awake, freely moving animals. Trends Pharmacol Sci 5:287–289CrossRefGoogle Scholar
  88. Van Riezen H, Schnieden H, Wren AF (1977): Olfactory bulb ablation in the rat: Behavioural changes and their reversal by antidepressive drugs. Br J Pharmacol 60:521–528PubMedGoogle Scholar
  89. Vernier VG, Hanson HM, Stone CA (1962): The pharmacodynamics of amitriptyline. In: Psychosomatic Medicine, Nodine JH, Moyer JH, eds. Philadelphia: Lea and FebigerGoogle Scholar
  90. Vetulani J, Dingell JV, Sulser F (1974): Effect of chronic treatment with desipramine (DMI) and iprindole (IP) on the norepinephrine (NE) sensitive adenylate cyclase system in slices of the rat limbic forebrain (LFS). The Pharmacologist 16:287Google Scholar
  91. Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976): A possible common mechanism of action of antidepressant treatments: Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn Schmiedebergs Arch Pharmacol 293:109–114PubMedCrossRefGoogle Scholar
  92. Vogel JR (1975): Antidepressants and mouse-killing (muricide) behavior In: Antidepressants, Fielding S, Lal H, eds. New York: FuturaGoogle Scholar
  93. Weatherall M (1985): How are drugs discovered? In: Pharmaceutical Medicine, Burley DM, Binns TB, eds. London: Edward ArnoldGoogle Scholar
  94. Weissman A, Koe BK (1987): Contributions of industrial research to basic neuropharmacology: Pre-clinical screening and discovery. In: Psychopharmacology: The Third Generation of Progress, Meltzer HY et al., eds. New York: Raven PressGoogle Scholar
  95. William JT, Henderson G, North RA (1985). Characterization of α 2 -adrenoceptors which increase potassium conductance in rat locus coeruleus neurones. Neuroscience 14:95–101CrossRefGoogle Scholar
  96. Willner P (1984): The validity of animal models of depression. Psychopharmacology 83:1–16PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1989

Authors and Affiliations

  • James L. Howard
  • Robert M. Ferris
  • Barrett R. Cooper
  • Francis E. Soroko
  • Ching M. Wang
  • Gerald T. Pollard

There are no affiliations available

Personalised recommendations